Disclosed are 4-{ 3-[6-amino-9-(3,4-dihydroxytetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl} -piperidine-1-carboxylic acid esters as represented by the general formulae I, II and III, wherein R1 and R2 independently are selected from H and C1-3alkyl Z is selected from cyclopropyl, cyclobutyl, cyclopentyl, tetrahydrofuranyl, azetidin-2-onyl, pyrrolidinyl, and pyrrolidin-2-onyl Z1 is selected from tetrahydrofuranyl, azetidin-2-onyl, pyrrolidinyl, and pyrrolidin-2-onyl wherein Z and / or Z1 are optionally substituted with 1 or 2 Z2 substituents R4 is selected from CH2OR and C(O)NRR each R independently is selected from H, alkyl, cyclobutyl, and (CH2)acyclopropyl q is selected from 1, 2, and 3 and wherein the remaining substituents are as defined herein. Also disclosed is a pharmaceutical composition which comprises a compound as defined above, or a stereoisomer and / or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, for the treatment of inflammation.
